← All Signals

🏥 FDA: Rising Pharma Holding, Inc. — Class II

healthcarebearishSource: FDA
83%Confidence
0Views
FDASource
2026-04-05Date

Summary

Rising Pharma's Temozolomide Capsules recall due to stability testing failures indicates potential quality degradation issues that could affect cancer treatment efficacy. This may impact patient trust and create supply vulnerabilities for this important chemotherapy medication.

Actionable: Review stability data for all Rising Pharma products and consider implementing additional quality verification measures.

AI Confidence: 83%

Data Points

firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now